Table 1.
Participant Demographic and Clinical Information
| AH (n = 42) | VH+AH (n = 40) | NH (n = 61) | HC (n = 155) | |
|---|---|---|---|---|
| Demographic info | ||||
| Age | 37.8 (11.9) | 37.2 (11.3) | 40.2 (11.8) | 37.8 (11.3) |
| Gender | 32 (m), 10 (f) | 30 (m), 10 (f) | 44 (m), 17 (f) | 110 (m), 45 (f) |
| Handedness (r/l/a) | 36 (r), 5 (l), 1 (a) | 33 (r), 5 (l), 2 (a) | 61 (r), 0 (l), 0 (a) | 146 (r), 7 (l), 2 (a) |
| Smoking status | 19 (s), 23 (n) | 20 (s), 20 (n) | 24 (s), 37 (n) | 14 (s), 141 (n) |
| Socioeconomic status subject*a | 50.8 (13.1) | 50.7 (13.7) | 50.2 (12.7) | 33.5 (12.8) |
| Socioeconomic status caregiver*b | 33.8 (14.8) | 35.0 (14.2) | 37.8 (14.5) | 30.51 (14.7) |
| Subject motion | ||||
| Mean framewise displacementc | 0.44 (0.3) | 0.42 (0.3) | 0.35 (0.2) | 0.30 (0.2) |
| Patient population | ||||
| Duration of Illness | 18.0 (11.0) | 17.0 (12.4) | 17.3 (11.5) | n/a |
| Chlorpromazine equiv. (CPZ Woods)d | 401.1 (443.1) | 335.4 (294.6) | 367.9 (356.2) | n/a |
| Total PANSS*e | 57.7 (12.6) | 63.3 (13.4) | 54.0 (13.1) | n/a |
| PANSS-positive*e | 16.6 (4.5) | 17.6 (4.1) | 12.9 (4.1) | n/a |
| PANSS-negative | 13.7 (5.3) | 15.2 (6.1) | 13.9 (4.7) | n/a |
| Total SAPS*f | 25.1 (13.3) | 40.0 (17.4) | 12.1 (12.3) | n/a |
| Total SAPS adjusted for 2 hallucination items*g | 21.8 (12.8) | 33.9 (16.5) | 12.1 (12.3) | n/a |
Note: HC, healthy control; AH, auditory hallucinations; NH, non-hallucinator; VH, visual hallucinations; PANSS, Positive and Negative Syndrome Scale; SAPS, Scale for the Assessment of Positive Symptoms.
aAH, VH+AH, and NH groups all significantly different than HC (Bonferroni post hoc, P < .01).
bNH vs HC significantly different (Bonferroni post hoc, P < .01).
cAH vs HC significantly different (Bonferroni post hoc, P < .01); VH vs HC significantly different (Bonferroni post hoc, P = .018).
dWe only had this information for a subset of patients; percent reporting = 80.4%.
eVH+AH vs NH significantly different (Bonferroni post hoc, P < .01).
fAH vs NH and VH+AH vs NH both significantly different (Bonferroni post hoc, P < .01).
gAll post hoc comparisons are significantly different (Bonferroni post hoc, P < .01).
*Group ANOVA is significant at P = .05.